RxDoctor Payments DataLook up a doctor →

Hedy Kindler

Hematology & Oncology · Chicago, ILNPI 1851453302

Payments from drug & device makers

$8,582,013in general payments, 2019–2025

Across 823 payments — averaging $10,428 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4.9M
  • Deciphera Pharmaceuticals Inc.$822K
  • Merck$605K
  • Novartis$601K
  • Bayer$379K
  • Roche Products Limited$323K
  • plus $923K from 13 others
$24,864in research payments, 2019–2025

Across 6 payments — averaging $4143.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Macrogenics, Inc.$24K
  • F. Hoffmann-la Roche AG$1K
  • Seagen Inc.$102

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca13$4,930,760
Deciphera Pharmaceuticals Inc.472$821,524
Merck29$604,930
Novartis15$600,643
Bayer84$378,805
Roche Products Limited24$322,604
Seagen Inc.81$291,479
Macrogenics, Inc.43$149,040
AbbVie14$110,961
GSK18$101,321
Astrazeneca UK Limited13$96,537
Pfizer1$75,994
Bristol Myers Squibb3$37,078
E.r. Squibb & Sons, L.L.C.5$26,342
Blueprint Medicines Corporation3$25,625
Sanofi US Services Inc.1$5,992
Novocure Inc.1$960
Amgen2$711
Organon1$707

How this compares

$8,582,013 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$55,252
Medicare patients
113
Services billed
615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →